Michael E. Prime

Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase

Michael E. Prime, Stephen M. Courtney, Frederick A. Brookfield et al. · Journal of Medicinal Chemistry · 2010 · 85 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Aurora Kinase Inhibitors +18

A Profiling Platform for the Characterization of Transglutaminase 2 (TG2) Inhibitors

Sabine Schaertl, Michael E. Prime, John Wityak et al. · SLAS DISCOVERY · 2010 · 74 citations · Full text

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease

Michael E. Prime, Ole A. Andersen, John J. Barker et al. · Journal of Medicinal Chemistry · 2012 · 69 citations · Full text

Structure–activity Relationship, Biochemistry, G Protein-coupled Receptor +12

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Leticia Toledo‐Sherman, Michael E. Prime, Ladislav Mrzljak et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Neurodegenerative Diseases +15

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand

Longbin Liu, Michael E. Prime, Matt R. Lee et al. · Journal of Medicinal Chemistry · 2020 · 55 citations